31 – 37 of 37
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- 3
- 4
- next »
- 2006
-
Mark
Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
(
- Contribution to journal › Article
- 2005
-
Mark
Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.
(
- Contribution to journal › Article
-
Mark
Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
(
- Contribution to journal › Article
-
Mark
Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up.
(
- Contribution to journal › Article
- 1998
-
Mark
S-phase fraction assessed by a variant of the rectangular model adapted to the flow-cytometric DNA histogram profile
(
- Contribution to journal › Letter
- 1997
-
Mark
Intra- and inter-laboratory reproducibility of estrogen and progesterone receptor enzyme immunoassay in breast cancer cytosol samples--a Swedish multicenter study. Swedish Society of Cancer Study Group
(
- Contribution to journal › Article
- 1995
-
Mark
Reproducibility in DNA flow cytometric analysis of breast cancer: comparison of 12 laboratories' results for 67 sample homogenates
(
- Contribution to journal › Article
- « previous
- 1
- 2
- 3
- 4
- next »